This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third View: Discussing Remternetug (LY3372993), an investigational monoclonal antibody being developed by Eli Lilly for the treatment of Alzheimer's Disease
Ticker(s): LLYWho's the expert?
Institution: Neurology Center of Lumberton
- board-certified in Neurology and Sleep Medicine
- expertise in diagnosing & treating Alzheimer's disease, Vascular dementia, Diffuse Lewy body dementia, Guillain-Barre syndrome and CIDP(chronic inflammatory demyelinating polyneuropathy),
- manages treatment for 36 patients with CIDP and 120 patients with Alzheimer's Disease
Interview Goalto discuss the standard of care and the potential of Remternetug (LY3372993) an investigational monoclonal antibody being developed by Eli Lilly for the treatment of Alzheimer's Disease.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
